TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of dermatologic cancers.

OVERVIEW OF ACTIVITY
Melanoma and nonmelanoma skin cancers — basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) — taken together, likely represent the most prevalent form of human cancer. The vast majority of skin cancer presents as minimally invasive BCC or SCC and is highly curable with local treatment alone. However, in rare instances these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, malignant melanoma is the most aggressive form of skin cancer, with a predilection toward distant metastases even when identified in the early stages. Thus, melanoma and nonmelanoma skin cancers are distinct entities, each posing unique challenges to the oncology community. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Identify patients after surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel these individuals regarding the risks and benefits of approved systemic approaches.
• Use biomarkers, clinical characteristics and mutational analyses to select individualized front-line and subsequent treatment approaches for patients with advanced melanoma.
• Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with BRAF tumor mutations.
• Recall the underlying research database guiding therapeutic recommendations for patients with locally advanced or metastatic SCC of the skin.
• Assess the rationale for and clinical trial data with anti-PD-1/PD-L1 antibodies for Merkel cell carcinoma, and optimally integrate available agents into current treatment algorithms.
• Formulate a long-term clinical plan for the management of locally advanced or metastatic BCC, incorporating existing and investigational treatments.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Michael A Postow, MD
Medical Oncologist
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committee: Array BioPharma Inc, Bristol-Myers Squibb Company, Incyte Corporation, Merck, NewLink Genetics Corporation, Novartis; Consulting Agreements: Bristol-Myers Squibb Company, Merck.

Karl Lewis, MD
Associate Professor of Medicine
Division of Medical Oncology
Director of the Melanoma Research Clinics
University of Colorado Denver
Aurora, Colorado

Advisory Committee: Array BioPharma Inc, Genentech, Incyte Corporation, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd; Contracted Research: AbbVie Inc, Aeglea BioTherapeutics, Array BioPharma Inc, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, Genentech, GlaxoSmithKline, Incyte Corporation, Iovance Biotherapeutics, Merck, Regeneron Pharmaceuticals Inc, Stemcentrx.

Mario Sznol, MD
Professor of Medicine, Medical Oncology
Leader, Melanoma/Renal Cell Disease Research Team
Co-Leader, Cancer Immunology Program
Smilow Cancer Hospital, Yale New Haven Hospital
Yale University School of Medicine
New Haven, Connecticut

Advisory Committee: Actym Therapeutics Inc, Adaptimmune Therapeutics, Adaptive Biotechnologies, Amphivena Therapeutics Inc, Intensity Therapeutics, Lycera, Molecular Partners, Omniox, Pieris Pharmaceuticals, Symphogen A/S; Consulting Agreements: AbbVie Inc, Allakos, Almac, Anaeropharma Science Inc, AstraZeneca Pharmaceuticals LP/MedImmune Inc, Biodesix Inc, Bristol-Myers Squibb Company, Celldex Therapeutics, Genentech, Genmab, Gritstone Oncology, Hinge Bio Inc, Incyte Corporation, Innate Pharma, Lilly, Merck, Nektar, Newlink Genetics Corporation, Pfizer Inc, Pierre Fabre, Seattle Genetics, Theravance Biopharma, Torque.

Professor Caroline Robert, MD, PhD
Chief, Dermato-Oncology
Co-Director, Melanoma Team INSERM
Gustave-Roussy Institute
Paris, France

Advisory Committee: Bristol-Myers Squibb Company, Incyte Corporation, Merck, Novartis, Roche Laboratories Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Merck, Novartis and Regeneron Pharmaceuticals Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: February 2019
Expiration date: February 2020